IN-VITRO ACTIVITY OF A NEW ANTIFUNGAL TRIAZOLE, D0870, AGAINST CANDIDA-ALBICANS ISOLATES FROM ORAL CAVITIES OF PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS

We investigated the in vitro activity of a new antifungal triazole, D0 870, against 100 Candida albicans isolates from the oral cavities of p atients infected,vith human immunodeficiency virus by using a broth ma crodilution method following the recommendations provided by the Natio nal Committee for Clinical Laboratory Standards (document M27-P). All of the isolates were chosen from C. albicans isolates already tested f or fluconazole susceptibility by the procedure of the National Committ ee for Clinical Laboratory Standards. Fifty isolates were considered f luconazole susceptible (MICs, less than or equal to 4 mu g/ml), and 50 isolates were considered fluconazole resistant (MICs, greater than or equal to 8 mu g/ml). The in vitro data demonstrated that D0870 had go od activity against isolates tested; for 90% of all strains of C. albi cans, MICs were 0.5 mu g/ml. However, the D0870 MICs for the fluconazo le-susceptible isolates were lower than those for the fluconazole-resi stant isolates; MICs for 50 and 90% of the isolates tested were less t han or equal to 0.0078 and 0.06 mu g/ml, respectively, for fluconazole -susceptible isolates and 0.25 and 2 mu g/ml, respectively, for flucon azole-resistant isolates (P < 0.001). Our data suggest that this new t riazole could represent a valid alternative in the treatment of oral c andidiasis in human immunodeficiency virus-infected patients.